Dr. Ming Tsao, Chair of Canadian Cancer Trials Group's Correlative Sciences Tumour Biology Committee, was recently presented with the Mary J. Matthews Pathology/Translational Research Award at the 16th World Conference on Lung Cancer.
Ming Tsao, MD, FRCPC, is Consultant Thoracic Pathologist, Senior Scientist, and M. Qasim Choksi Chair in Lung Cancer Translational Research at the Princess Margaret Cancer Centre. Additionally, he is a Professor of Laboratory Medicine and Pathobiology and Medical Biophysics at the University of Toronto.
Dr. Tsao has been Director of the Canadian Institutes of Health Research training program in molecular pathology of cancer since 2002; Co-Director of the Advanced Optical Micro-imaging Facility, Ontario Cancer Institute; Director of the Advanced Molecular Profiling and Drug Discover Program; and Biomarker Laboratory member of the Canadian Cancer Society Advisory Committee on Research. His current lung cancer research activities include biomarkers in targeted cancer therapy, molecular prognostic and predictive markers and pathobiology of lung cancer, tumor cell stromal interaction, Ras oncogene, and application of novel optical/Raman technologies for tissue/ cellular and in vivo imaging.
Dr. Tsao earned his medical degree at the University of British Columbia and his FRCPC at Royal College of Physicians and Surgeons of Canada. He served his residency in anatomic pathology at McGill University in Montreal, followed by a fellowship in experimental pathology at the University of North Carolina. He has served on the Editorial Board of the Journal of Clinical Oncology and as a member of the International Advisory Board of the Canadian Journal of Pathology.
In 2010, the Canadian Cancer Society honored Dr. Tsao with the 2011 O. Harold Warwick Award in recognition of his extraordinary contributions and work toward advancing the science of lung cancer.
About the Mary J. Matthews Pathology/Translational Research Award
The Mary J. Matthews Pathology/ Translational Research Award is given to an International Association for the Study of Lung Cancer (IASLC) scientist for lifetime scientific achievements in pathology/translational research of thoracic malignancies.
Dr. Matthews was a Senior Investigator and Pathologist at the National Cancer Institute (NCI) Medical Oncology Branch and a pioneer in the foundation of the histological subtypes of lung cancer and the relationship between those subtypes and the clinical course of lung cancer. She was the first to recognize that small cell lung cancer was disseminated at the time of diagnosis, leading to distinctions between small cell lung cancer and non-small cell lung cancer.